MYLK4: Potential Drug Target and Biomarker for Muscle Tissue Regulation

Target Name: MYLK4

NCBI ID: G340156

MYLK4

MYLK4: Potential Drug Target and Biomarker for Muscle Tissue Regulation

Myosin light chain kinase (MYLK4) is a protein that plays a crucial role in the regulation of muscle contractions and the development of muscle tissue. It is a member of the myosin light chain kinase family, which is known for its ability to regulate the myosin ATPase, a critical enzyme that generates ATP through a phosphate-protein interaction.MYLK4 is expressed in a wide range of tissues, including muscle, heart, and brain, and has been implicated in a number of physiological processes.

Drug Targeting

MYLK4 has been identified as a potential drug target due to its involvement in muscle contractions and the regulation of myosin ATPase activity.MYLK4 has been shown to play a role in the regulation of muscle contractions, including the rapid and rapid changes that occur during muscle relaxation. It has also been shown to play a role in the regulation of myosin ATPase activity, which is a critical enzyme that generates ATP through a phosphate-protein interaction.

MYLK4 has been shown to regulate the activity of myosin ATPase in a number of different muscle fibers, including cardiac muscle and skeletal muscle. It has been shown to increase the activity of myosin ATPase, which can lead to increased muscle contractions and the development of muscle tissue.

In addition to its role in muscle contractions, MYLK4 has also been shown to play a number of other roles in the regulation of myosin ATPase activity. It has been shown to regulate the stability of myosin ATPase, which is important for its ongoing activity. It has also been shown to regulate the sensitivity of myosin ATPase to inhibitors, which can help to regulate its activity in response to changes in the environment.

Biomarker

MYLK4 has also been shown to be a potential biomarker for a number of different conditions. For example, it has been shown to be elevated in the blood of patients with heart failure, a condition in which the heart is not able to pump enough blood to meet the needs of the body. It has also been shown to be elevated in the blood of patients with hypertension, a condition in which the blood pressure is too high.

MYLK4 has also been shown to be involved in the regulation of a number of other physiological processes, including the development and maintenance of blood vessels, the regulation of inflammation, and the regulation of cell growth.

Conclusion

In conclusion, MYLK4 is a protein that plays a crucial role in the regulation of muscle contractions and the development of muscle tissue. It is a member of the myosin light chain kinase family and has been shown to play a role in a number of physiological processes. As a potential drug target, MYLK4 has the potential to be used to treat a wide range of conditions, including heart failure, hypertension, and inflammation. Further research is needed to fully understand the role of MYLK4 in these processes and to develop effective treatments.

Protein Name: Myosin Light Chain Kinase Family Member 4

The "MYLK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYLK4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets